Cargando…
SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses
Approved neutralizing antibodies that target the prototype Spike are losing their potency against the emerging variants of concern (VOCs) of SARS-CoV-2, particularly Omicron. Although SARS-CoV-2 is continuously adapting the host environment, emerging variants recognize the same ACE2 receptor for cel...
Autores principales: | Shah, Masaud, Ung Moon, Sung, Hyun Kim, Jang, Thanh Thao, Trinh, Goo Woo, Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040525/ https://www.ncbi.nlm.nih.gov/pubmed/35495107 http://dx.doi.org/10.1016/j.csbj.2022.04.030 |
Ejemplares similares
-
Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies
por: Shah, Masaud, et al.
Publicado: (2022) -
Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
por: Shah, Masaud, et al.
Publicado: (2023) -
Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles
por: Wu, Canhao, et al.
Publicado: (2022) -
Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
por: Shah, Masaud, et al.
Publicado: (2020) -
Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants
por: Sun, Hancong, et al.
Publicado: (2022)